title: Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature.
abstract: Blast phase in chronic myelogenous leukemia (CML) has rarely been reported to involve extramedullary sites like skin, lymph nodes, and central nervous system. Clinical history, characteristic hematologic findings (elevated leukocyte counts, myelocytic predominance, and basophilia), and Philadelphia chromosome are of high diagnostic significance especially in isolated extramedullary presentations. We describe a unique case of CML relapse with blast phase involving the eye. A 66-year-old man with a known diagnosis of CML on imatinib and in molecular remission for 3 years presented with a painful blind eye. Histologic examination revealed diffuse involvement of choroid, iris, vitreous humor, and the optic nerve by blast cells. The blasts expressed CD34, aberrant TdT, and a myeloid phenotype (CD13, CD33, and CD117). Fluorescence in situ hybridization (FISH) of vitreous fluid detected BCR-ABL1 gene rearrangement. Additionally, trisomy 8 and gains of 9 and 22 were seen which were not present in the initial diagnostic marrow study 3 years ago. At relapse, the bone marrow, peripheral blood, and the cerebrospinal fluid were not involved by CML. Patient received induction chemotherapy and single dose prophylactic intrathecal methotrexate and was maintained on antityrosine kinase therapy and eventually underwent allogenic stem cell transplantation.
authors.affiliation: Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.
authors.forename: Rohit
authors.initials: R
authors.lastname: Gulati
authors.affiliation: Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.
authors.forename: Yaser
authors.initials: Y
authors.lastname: Alkhatib
authors.affiliation: Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.
authors.forename: Vijayalakshmi
authors.initials: V
authors.lastname: Donthireddy
authors.affiliation: Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.
authors.forename: Michelle Madden
authors.initials: MM
authors.lastname: Felicella
authors.affiliation: Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.
authors.forename: Madhu P
authors.initials: MP
authors.lastname: Menon
authors.affiliation: Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, MI 48202, USA.
authors.forename: Kedar V
authors.initials: KV
authors.lastname: Inamdar
references.citation: Blood. 2002 Oct 1;100(7):2292-302
references.pmid: 12239137
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2076-81
references.pmid: 18250304
references.citation: Onkologie. 2013;36(3):119-22
references.pmid: 23486000
references.citation: Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Jun;22(3):629-33
references.pmid: 24989266
references.citation: Cell. 2012 Mar 30;149(1):22-35
references.pmid: 22464321
references.citation: Oncogene. 2014 Oct 16;33(42):5028-38
references.pmid: 24747972
references.citation: BMC Blood Disord. 2012 Aug 07;12:9
references.pmid: 22871019
references.citation: Intern Med J. 2009 Jun;39(6):408-11
references.pmid: 19580620
references.citation: Haematologica. 1990 Mar-Apr;75(2):146-8
references.pmid: 2358205
references.citation: Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):117-21
references.pmid: 19402798
references.citation: Am J Clin Pathol. 2007 Apr;127(4):642-50
references.pmid: 17369142
references.citation: Rom J Intern Med. 2012 Jul-Sep;50(3):241-4
references.pmid: 23330292
references.citation: Leuk Res Rep. 2013 Aug 13;2(2):67-9
references.pmid: 24371785
references.citation: Genet Mol Res. 2014 Feb 19;13(1):945-53
references.pmid: 24634115
references.citation: Ann Hematol. 2015 Apr;94 Suppl 2:S123-31
references.pmid: 25814078
references.citation: Am J Hematol. 1993 May;43(1):10-3
references.pmid: 8317457
references.citation: Blood. 2008 Aug 15;112(4):1005-12
references.pmid: 18477770
references.citation: Blood. 2004 Jun 1;103(11):4010-22
references.pmid: 14982876
references.citation: Leuk Lymphoma. 1995 Dec;20(1-2):161-3
references.pmid: 8750639
references.citation: Leuk Res. 1996 Nov-Dec;20(11-12):905-8
references.pmid: 9009247
references.citation: Cancer Genet Cytogenet. 1994 Sep;76(2):151-3
references.pmid: 7923067
references.citation: Leuk Lymphoma. 2004 Feb;45(2):401-3
references.pmid: 15101732
references.citation: Leuk Res. 2015 Mar;39(3):329-34
references.pmid: 25612940
references.citation: Cancer. 2015 Mar 15;121(6):872-5
references.pmid: 25387987
references.citation: Haematologica. 1996 Sep-Oct;81(5):423-7
references.pmid: 8952155
references.citation: Leukemia. 2006 Dec;20(12):2137-46
references.pmid: 17082780
references.citation: Leuk Lymphoma. 2004 Apr;45(4):695-8
references.pmid: 15160941
references.citation: Leuk Res. 2010 Apr;34(4):e113-4
references.pmid: 19811825
references.citation: Diagn Cytopathol. 2013 Mar;41(3):253-6
references.pmid: 23417967
references.citation: Blood. 2014 Jun 19;123(25):3932-42
references.pmid: 24825862
references.citation: Leuk Lymphoma. 1993;11 Suppl 1:235-7
references.pmid: 8251902
references.citation: Eye (Lond). 2004 Jul;18(7):663-72
references.pmid: 15002029
references.citation: Sangre (Barc). 1990 Jun;35(3):236-7
references.pmid: 2396171
references.citation: FEBS Lett. 2000 May 4;473(1):47-52
references.pmid: 10802057